Kruisbloemige groenten blokkeren groei longkanker.*
Isothiocyanaten, een bestanddeel van kruisbloemige groenten zoals broccoli, div. koolsoorten en waterkers blijken uit een paar studies zowel bij muizen als in het laboratorium met menselijke cellen de ontwikkeling van longkankercellen sterk te kunnen doen verminderen. Hoe precies is niet bekend en dat zal in verdere studies nog moeten blijken.
Compounds
in broccoli, cauliflower, and watercress block lung cancer progression
They say the results, published in a set of papers in the September 15 issue of
Cancer Research, suggest that these chemicals -- put into a veggie pill of sorts
-- might some day be used to help current and former smokers ward off
development of lung cancer, the leading cause of cancer death in Americans.
"These studies provides significant insight into the mechanisms of lung
cancer prevention and suggests ways the
process can be slowed down after exposure has already occurred," said the
study's principal investigator Fung-Lung Chung, Ph.D., Professor of Oncology in
the Lombardi Cancer Center at the Georgetown University Medical Center. He
worked with researchers from the Institute for Cancer Prevention, in Valhalla,
New York, and with other scientists in Illinois, Minnesota and New York on the
studies.
"We still need to do more research, but it may be that an agent containing
these ingredients could, to some degree, help protect people who have developed
early lung lesions due to smoking," Chung said. "In any case, we know
that eating vegetables is generally good for us, and that some studies have
shown they help lower a person's risk of developing cancer."
One of the two new studies being reported was the first to test whether these
compounds, derived from naturally occurring isothiocyanates, could have an
impact on the stages of cancer development specifically after exposure to
cancer-causing elements . To test that, the researchers induced lung tumor
development in experimental mice by exposing them to tobacco carcinogens, and
then they fed one group of mice the veggie compounds. They found that, indeed,
use of the chemicals resulted in a reduced development of benign (harmless) lung
tumors to malignant tumors, compared to mice that did not receive the compound.
Chung cautions, however, that it is difficult to draw any direct comparisons
between human consumption of these vegetables and the effects seen in the mice
studies. "Because the amount of carcinogens we used to induce tumors was
very high, we needed to use a very high dose of isothiocyanates to see any
effect," he said. "This animal model will give us data for the
potential use of such agents in a human clinical trial."
The second new study looked at the effect of the same compound on human lung
cancer cells, which were forced to grow
quickly (as cancer does) because of insertion of a gene known to be involved in
cell growth and regulation. The laboratory test showed that the derivative of
isothiocyanate significantly pushed the human lung cells to commit "suicide,"
compared to cells that did not have the gene, suggesting that its use may stop
fast growing lung cancer cells from the outset. This study provides some
insight onto "one of the possible mechanisms of action" by which the
compounds may offer some protection against lung
cancer development, the researchers said.
These studies were continuation of a 20-year research effort by Chung and his
team, much of it conducted while Chung was at the Institute for Cancer
Prevention before moving to Georgetown University Medical Center. The body of
research they have established on the connection between cruciferous vegetables
and lung cancer is one of the most detailed available. Chung earlier identified
the isothiocyanates may be responsible for the beneficial effects of these
vegetables, and he had shown they were effective in hindering development of
lung cancer cells.
The study was funded by a grant from the National Institutes of Health.
Co-authors include C. Clifford Conaway, PhD, from the Institute for Cancer
Prevention, who served as senior investigator on the mouse study, and Yang-Ming
Yang, PhD, also from the Institute, who was first author on the lung cell study.
Other co-authors include, from the Institute for Cancer Research, Meena
Jhanwar-Uniyal, PhD, Joel Schwartz, MD, Chung-Xiou Wang, MD, and Brian Pittman,
MS; Defa Tian, MD, from Georgetown University; H. Dorota Halicka, PhD, and Frank
Traganos, PhD, from New York Medical College; and Edward McIntee, PhD, and
Stephen Hecht, PhD, from the University of Minnesota.( Sept. 2005)